- Home
- » Tags
- » Panitumumab
Top View
- Cetuximab and Panitumumab for Previously Untreated Metastatic Colorectal Cancer
- CDER List of Licensed Biological Products With
- Clinical Potential of Necitumumab in Non-Small Cell Lung Carcinoma
- Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer Funda Meric-Bernstam1,2,3, Amber M
- Spotlight on Necitumumab in the Treatment of Non-Small-Cell Lung Carcinoma
- 099 Quality Care Cancer Program (Medical Oncology)
- Assessment Report
- Vectibix (Panitumumab) Is a Recombinant, Human Igg2 Kappa Monoclonal Antibody That Binds Specifically to the Human Epidermal Growth Factor Receptor (EGFR)
- DAIICHI SANKYO CO., LTD. Sunao Manabe President and CEO June 8, 2021
- Specialty Injectables Prior Authorization List
- Chemotherapy: Drugs P-Z Policy (Chemo Drug P-Z)
- “What's New” Medical Pharmaceutical Policy Updates March
- Candidate Biomarkers for Specific Intraoperative Near-Infrared
- Table 1. Summary of Kinase Inhibitors Approved by the FDA for Treatment
- Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance Atrish Bagchi1,2, Jaafar N
- Oncology Medications Policy (1403)
- Co-Treatment with Panitumumab and Trastuzumab Augments Response
- U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer
- Oncology Therapy for the Generalist
- An Anti-Egfr ׀‰Cotinine Bispecific Antibody Complexed With
- Toxicology Section of the NCI/CIP IND for 89Zr-Panitumumab. This
- Molecular Imaging Reveals Trastuzumab-Induced Epidermal Growth Factor Receptor Downregulation in Vivo
- Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-Type Metastatic Colorectal Cancer
- 2019-02-26 ENFORSED FILED Complaint Copy
- List of Cleared Or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
- A Systematic Review of Head-To-Head Trials of Approved Monoclonal
- June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
- FAQ: Oncology Home Infusion Program
- Monoclonal Antibodies As Therapeutic Agents in Oncology and Antibody Gene Therapy
- Efficacy of Sym004 in Patients with Metastatic Colorectal Cancer With
- Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric Or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1A/B JVDF Trial
- Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer
- Trastuzumab Panitumumab Bevacizumab Cetuximab
- Corporate Medical Policy Panitumumab (Vectibix®)
- Activity of Panitumumab Alone Or with Chemotherapy in Non-Small Cell Lung Carcinoma Cell Lines Expressing Mutant Epidermal Growth Factor Receptor
- Global Oncology
- Panitumumab and Cetuximab Toxicity Management Guidelines
- Precision Cancer Therapy
- An Open Access Database of Licensed Cancer Drugs Pan Pantziarka 1,2, §, Rica Capistrano 1, Arno De Potter 3, Liese Vandeborne 1, Gauthier Bouche 1
- Egfrviii-Mediated Transactivation of Receptor Tyrosine Kinases in Glioma: Mechanism and Therapeutic Implications
- 125547Orig1s000
- Vectibix® (Panitumumab)
- 5.01.603 Epidermal Growth Factor Receptor (EGFR) Inhibitors
- Monoclonal Antibodies in Cancer Therapy
- Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer
- Vectibix, INN-Panitumumab
- Bevacizumab Or Cetuximab Or Crizotinib Or Dasatinib Or
- Has Approved Aloxi® (Palonosetron HCI) Cyramza™ (Ramucirumab)For
- Targeted Therapy in Esophageal Cancer
- Ramucirumab in the Second-Line Treatment of Metastatic Colorectal Cancer: a Narrative Review of Literature from Clinical Trials
- Systemic Therapy Update
- Updated Insights on EGFR Signaling Pathways in Glioma
- Tyrosine Kinase-Targeting Drugs-Associated Heart Failure